title: [Antipsychotic use in the cohort PACA-Alz in patients with Alzheimer's disease and other dementia in 2010].
abstract: OBJECTIVE
  The aim of the study was to identify and to characterize patients with Alzheimer's disease or related dementia describing antipsychotics and other psychotropic expositions.
  
  
  METHODS
  The study was performed, in 2010, based on Provence-Alpes-Côte d'Azur region (PACA)-Corse Alz cohort included patients with dementia, with chronic condition 'Alzheimer disease or related disease' and/or had at least one delivery of Alzheimer's specific treatment, registered in the General Health Care System. Psychotropic drugs were extracted according anatomical, therapeutical and chemical code. Chronic exposure defined as more than 3 consecutive deliveries.
  
  
  RESULTS
  Among 34 696 included patients, 26.9% were men and 68.8% were 80 years old and more. Among them, 26% received at least one antipsychotic medication, with a chronic exposition estimated around 61.3%. Antidepressant and anxiolytic were consumed respectively by 47% and 45.3% of patients. Risperidone was the most used antipsychotic (11.2%). The Health care use (hospitalizations, nurses and physicians visits) was significantly higher among patients with antipsychotics.
  
  
  CONCLUSIONS
  Antipsychotics use in patients with dementia remains high. The follow up of this regional cohort would be helpful to identify the impact of guidelines on the prescription and the care of patients with dementia.
authors.affiliation: Aix-Marseille Université, Institut de Neurosciences Timone, UMR CNRS 7289, Marseille, France - Service de Médecine interne Gériatrie, Assistance publique - Hôpitaux de Marseille, Marseille, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Bonin-Guillaume
authors.affiliation: Service de Médecine interne Gériatrie, Assistance publique - Hôpitaux de Marseille, Marseille, France.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Martin
authors.affiliation: Laboratoire de Santé publique, Assistance publique - Hôpitaux de Marseille, Marseille, France.
authors.forename: Joseline
authors.initials: J
authors.lastname: Zafack
authors.affiliation: Aix-Marseille Université, Département universitaire de Médecine générale, Faculté de Médecine, Marseille, France.
authors.forename: Gaétan
authors.initials: G
authors.lastname: Gentile
authors.affiliation: Direction régionale du Service médical de l'Assurance maladie Provence - Alpes - Côte d'Azur-Corse, Marseille, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Allaria-Lapierre
authors.affiliation: Direction régionale du Service médical de l'Assurance maladie Provence - Alpes - Côte d'Azur-Corse, Marseille, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Sciortino
authors.affiliation: Laboratoire de Santé publique, Assistance publique - Hôpitaux de Marseille, Marseille, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Thirion
authors.affiliation: Aix-Marseille Université, Institut de Neurosciences Timone, UMR CNRS 7289, Marseille, France - CIC-Centre de Pharmacologie clinique et d'Evaluations thérapeutiques, Service de Pharmacologie médicale et Pharmacovigilance, Marseille, France.
authors.forename: Joëlle
authors.initials: J
authors.lastname: Micallef
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D003695:Delivery of Health Care / Q000706:statistics & numerical data; D003704:Dementia / Q000188:drug therapy*; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000627:therapeutic use*; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D018967:Risperidone